AstraZeneca's Imfinzi Initiates Phase II Clinical Trial for Neoadjuvant Therapy in Surgically Resectable High-Risk Biliary Tract Cancer
Expanding into Neoadjuvant Therapy
This Phase II clinical trial, led by the National Cancer Institute (NCI) and MD Anderson Cancer Center, evaluates the efficacy of Imfinzi (active ingredient: durvalumab) in combination with gemcitabine and cisplatin in 27 patients with surgically resectable high-risk intrahepatic cholangiocarcinoma (iCCA). This represents an attempt to expand Imfinzi's therapeutic area from advanced biliary tract cancer to neoadjuvant therapy, administered before surgery. Biliary tract cancer has limited treatment options, as only 20% of patients are diagnosed at a stage where surgery is possible, and even after surgery, recurrence rates can reach up to 60%. This trial can be interpreted as a strategic move to maximize the rate of complete tumor resection and improve survival by reducing tumor size.
Differentiated Triple Combination Therapy Mechanism
The mechanism of action in this trial involves combining Imfinzi, an immune checkpoint inhibitor targeting programmed cell death ligand 1 (PD-L1), with two standard chemotherapy agents. While the immune checkpoint inhibitor blocks the immune evasion of cancer cells, gemcitabine and cisplatin inhibit DNA synthesis and induce cell death, delivering a dual attack. This combination therapy aims to induce immune activation in the microenvironment, eliminate early micrometastases before surgery, and increase the likelihood of successful surgery. This goes beyond simply extending survival and has significant clinical value in potentially improving the chances of a cure.
Market Leadership Strategy Based on Phase III Data
Imfinzi has already secured market dominance by obtaining FDA approval in September 2022 as a first-line treatment for locally advanced or metastatic biliary tract cancer, based on the results of the Phase III (TOPAZ-1) trial. It became the first standard of care for biliary tract cancer by improving overall survival (OS) compared to the standard treatment. AstraZeneca is not resting on its laurels and is diversifying its indications to include pre- and post-operative adjuvant therapy, aiming to further widen the gap with its competitors. With the global biliary tract cancer market projected to grow to $1.9 billion by 2026, this expansion will solidify its market position.
Fierce Competition with Keytruda and Future Value
Currently, in the biliary tract cancer market, MSD's Keytruda (active ingredient: pembrolizumab) is rapidly catching up to Imfinzi, based on the approval of its Phase III (KEYNOTE-966) trial. Keytruda is also actively conducting Phase II/III clinical trials for pre- and post-operative adjuvant therapy in patients eligible for surgery, engaging in a battle for leadership in the immune checkpoint inhibitor market. In this Phase II trial, Imfinzi needs to demonstrate data on complete resection (R0 margin-negative resection) and pathological complete response (pCR) to gain a clear comparative advantage in the later stages of clinical trials and regulatory approvals. If positive results are obtained by the expected primary completion date of February 2027, the global revenue growth of Imfinzi is expected to accelerate further.
Imfinzi is a key blockbuster drug for AstraZeneca, generating $6.06 billion in annual revenue in 2025, and this Phase II trial is a strategic effort to expand the prescription target for Imfinzi to include the pre-operative adjuvant therapy group in the global biliary tract cancer market, estimated at $1.9 billion by 2026. In the short term, whether Imfinzi can achieve a key milestone in improving the survival of patients with surgically resectable high-risk biliary tract cancer will be determined by the results of pathological complete response (pCR) and R0 resection rate, expected by the primary completion date of February 2027. In the medium to long term, with MSD's Keytruda gaining ground as a latecomer based on the approval of the KEYNOTE-966 trial, establishing clinical superiority in the pre- and post-operative adjuvant therapy area will be a turning point in determining the future landscape of the biliary tract cancer immune checkpoint inhibitor market. This trial has the potential to establish Imfinzi as a standard treatment encompassing patients eligible for surgery, beyond its status as the first FDA-approved drug for advanced biliary tract cancer, and to drive long-term revenue growth in AstraZeneca's oncology division.
Source: ClinicalTrials.gov (api_ct)